Marulli Giuseppe, Battistella Lucia, Perissinotto Egle, Breda Cristiano, Favaretto Adolfo Gino, Pasello Giulia, Zuin Andrea, Loreggian Lucio, Schiavon Marco, Rea Federico
Department of Cardiologic, Thoracic and Vascular Sciences, Thoracic Surgery Unit, University of Padova, Padova, Italy
Department of Cardiologic, Thoracic and Vascular Sciences, Thoracic Surgery Unit, University of Padova, Padova, Italy.
Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):805-11; discussion 811-2. doi: 10.1093/icvts/ivv032. Epub 2015 Mar 10.
Pancoast tumour is a rare neoplasia in which the optimal therapeutic management is still controversial. The traditional treatment of Pancoast tumour (surgery, radiotherapy or a combination of both) have led to an unsatisfactory outcome due to the high rate of incomplete resection and the lack of local and systemic control. The aim of the study was to determine the efficacy of the trimodality approach.
Fifty-six patients (male/female ratio: 47/9, median age: 64 years) in stage IIB to IIIB were treated during a period between 1994 and 2013. Induction therapy consisted of 2-3 cycles of a platinum-based chemotherapy associated with radiotherapy (30-44 Gy). After restaging, eligible patients underwent surgery 2 to 4-week post-radiation.
Thirty-two (57.1%) patients were cT3 and 24 (42.9%) cT4, 47 (83.9%) were N0 and 9 (16.1%) N+. Forty-eight (85.7%) patients underwent R0 resection and 10 (17.9%) had a complete pathological response (CPR). Thirty-day mortality rate was 5.4%, major surgical complications occurred in 6 (10.7%) patients. At the end of the follow-up, 17 (30.4%) patients were alive and 39 (69.6%) died (29 for cancer-related causes), with an overall 5-year survival of 38%. At statistical analysis, stage IIB (P = 0.003), R0 resection (P = 0.03), T3 tumour (P = 0.002) and CPR (P = 0.01) were significant independent predictors of better prognosis.
This combined approach is feasible, and allows for a good rate of complete resection. Long-term survival rates are acceptable, especially for early stage tumours radically resected. Systemic control of disease still remains poor, with distant recurrence being the most common cause of death.
肺上沟瘤是一种罕见的肿瘤,其最佳治疗方案仍存在争议。由于不完全切除率高以及缺乏局部和全身控制,传统的肺上沟瘤治疗方法(手术、放疗或两者结合)导致的治疗效果并不理想。本研究的目的是确定三联疗法的疗效。
1994年至2013年期间,对56例IIB至IIIB期患者(男女比例:47/9,中位年龄:64岁)进行了治疗。诱导治疗包括2 - 3个周期的铂类化疗联合放疗(30 - 44 Gy)。重新分期后,符合条件的患者在放疗后2至4周接受手术。
32例(57.1%)患者为cT3,24例(42.9%)为cT4,47例(83.9%)为N0,9例(16.1%)为N +。48例(85.7%)患者接受了R0切除,10例(17.9%)有完全病理缓解(CPR)。30天死亡率为5.4%,6例(10.7%)患者发生了严重手术并发症。随访结束时,17例(30.4%)患者存活,39例(69.6%)死亡(29例因癌症相关原因),总体5年生存率为38%。经统计学分析,IIB期(P = 0.003)、R0切除(P = 0.03)、T3肿瘤(P = 0.002)和CPR(P = 0.01)是预后较好的显著独立预测因素。
这种联合治疗方法是可行的,并且能够实现较高的完全切除率。长期生存率是可以接受的,尤其是对于早期肿瘤进行根治性切除的患者。疾病的全身控制仍然较差,远处复发是最常见的死亡原因。